564 related articles for article (PubMed ID: 25349172)
21. Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers.
Lugli G; Cohen AM; Bennett DA; Shah RC; Fields CJ; Hernandez AG; Smalheiser NR
PLoS One; 2015; 10(10):e0139233. PubMed ID: 26426747
[TBL] [Abstract][Full Text] [Related]
22. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
[TBL] [Abstract][Full Text] [Related]
23. Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects.
Nagaraj S; Laskowska-Kaszub K; Dębski KJ; Wojsiat J; Dąbrowski M; Gabryelewicz T; Kuźnicki J; Wojda U
Oncotarget; 2017 Mar; 8(10):16122-16143. PubMed ID: 28179587
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA Expression Signature in Mild Cognitive Impairment Due to Alzheimer's Disease.
De Felice B; Montanino C; Oliva M; Bonavita S; Di Onofrio V; Coppola C
Mol Neurobiol; 2020 Nov; 57(11):4408-4416. PubMed ID: 32737762
[TBL] [Abstract][Full Text] [Related]
25. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.
Nho K; Kueider-Paisley A; Ahmad S; MahmoudianDehkordi S; Arnold M; Risacher SL; Louie G; Blach C; Baillie R; Han X; Kastenmüller G; Trojanowski JQ; Shaw LM; Weiner MW; Doraiswamy PM; van Duijn C; Saykin AJ; Kaddurah-Daouk R;
JAMA Netw Open; 2019 Jul; 2(7):e197978. PubMed ID: 31365104
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma.
Bekris LM; Lutz F; Montine TJ; Yu CE; Tsuang D; Peskind ER; Leverenz JB
Biomarkers; 2013 Aug; 18(5):455-66. PubMed ID: 23822153
[TBL] [Abstract][Full Text] [Related]
27. Emergence of exosomal miRNAs as a diagnostic biomarker for Alzheimer's disease.
Van Giau V; An SS
J Neurol Sci; 2016 Jan; 360():141-52. PubMed ID: 26723991
[TBL] [Abstract][Full Text] [Related]
28. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease.
Geekiyanage H; Jicha GA; Nelson PT; Chan C
Exp Neurol; 2012 Jun; 235(2):491-6. PubMed ID: 22155483
[TBL] [Abstract][Full Text] [Related]
29. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
Dukart J; Sambataro F; Bertolino A
J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
[TBL] [Abstract][Full Text] [Related]
30. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
[TBL] [Abstract][Full Text] [Related]
31. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease.
Kiko T; Nakagawa K; Tsuduki T; Furukawa K; Arai H; Miyazawa T
J Alzheimers Dis; 2014; 39(2):253-9. PubMed ID: 24157723
[TBL] [Abstract][Full Text] [Related]
32. Identification of blood biomarkers for use in point of care diagnosis tool for Alzheimer's disease.
Jammeh E; Zhao P; Carroll C; Pearson S; Ifeachor E
Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():2415-2418. PubMed ID: 28268812
[TBL] [Abstract][Full Text] [Related]
33. Lower Serum Levels of miR-29c-3p and miR-19b-3p as Biomarkers for Alzheimer's Disease.
Wu Y; Xu J; Xu J; Cheng J; Jiao D; Zhou C; Dai Y; Chen Q
Tohoku J Exp Med; 2017 Jun; 242(2):129-136. PubMed ID: 28626163
[TBL] [Abstract][Full Text] [Related]
34. Elevated plasma levels of exosomal BACE1‑AS combined with the volume and thickness of the right entorhinal cortex may serve as a biomarker for the detection of Alzheimer's disease.
Wang D; Wang P; Bian X; Xu S; Zhou Q; Zhang Y; Ding M; Han M; Huang L; Bi J; Jia Y; Xie Z
Mol Med Rep; 2020 Jul; 22(1):227-238. PubMed ID: 32377715
[TBL] [Abstract][Full Text] [Related]
35. MiRNA -483-5p as a Potential Noninvasive Biomarker for Early Detection of Alzheimer's Disease.
Sabry R; El Sharkawy RE; Gad NM
Egypt J Immunol; 2020 Jun; 27(2):59-72. PubMed ID: 33548978
[TBL] [Abstract][Full Text] [Related]
36. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.
Lim YY; Villemagne VL; Laws SM; Pietrzak RH; Snyder PJ; Ames D; Ellis KA; Harrington K; Rembach A; Martins RN; Rowe CC; Masters CL; Maruff P
Mol Psychiatry; 2015 Nov; 20(11):1322-8. PubMed ID: 25288138
[TBL] [Abstract][Full Text] [Related]
37. Apolipoprotein E4 serum concentration for increased sensitivity and specificity of diagnosis of drug treated Alzheimer's disease patients vs. drug treated parkinson's disease patients vs. age-matched normal controls.
Goldknopf IL; Park HR; Sabbagh M
Curr Alzheimer Res; 2012 Dec; 9(10):1149-67. PubMed ID: 22950864
[TBL] [Abstract][Full Text] [Related]
38. Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases.
Barbagallo C; Mostile G; Baglieri G; Giunta F; Luca A; Raciti L; Zappia M; Purrello M; Ragusa M; Nicoletti A
Cell Mol Neurobiol; 2020 May; 40(4):531-546. PubMed ID: 31691877
[TBL] [Abstract][Full Text] [Related]
39. Serum MicroRNA Profiles Serve as Novel Biomarkers for the Diagnosis of Alzheimer's Disease.
Dong H; Li J; Huang L; Chen X; Li D; Wang T; Hu C; Xu J; Zhang C; Zen K; Xiao S; Yan Q; Wang C; Zhang CY
Dis Markers; 2015; 2015():625659. PubMed ID: 26078483
[TBL] [Abstract][Full Text] [Related]
40. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
